TrialClinical pharmacokinetics2021
An Exposure-Response Analysis of the Clinical Efficacy of Ponesimod in a Randomized Phase II Study in Patients with Multiple Sclerosis.
Per Olsson Gisleskog et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
2 papers cite it
this papertrialcites it